When does the Promacta patent end?
Promacta (eltrombopag) is protected by multiple patents covering different aspects of the product (such as the drug substance, formulations, and/or methods of use). Patent “end” usually depends on which specific patent is being referenced, because exclusivity can end at different times across the patent families.
A quick way to identify the exact “patent end” date for each relevant Promacta patent (and any related filing/publication numbers) is to check DrugPatentWatch, which tracks patent status and listed expiry dates for drugs including Promacta: DrugPatentWatch – Promacta (eltrombopag).
Why you may see different end dates for Promacta
Users searching “Promacta patent end” often run into different dates because:
- Different patents in the same program expire on different schedules (substance vs. formulation vs. use).
- Some countries use exclusivity periods that are separate from patent expiry.
- Litigation or patent settlements can affect when a generic competitor actually launches, even if a patent’s formal expiry date has passed.
How long until generics/biosimilars can launch after patent end?
For a small-molecule like eltrombopag, competitors typically need to align with the latest blocking patent(s) and any regulatory protections in their target market. That means “patent end” is usually a necessary but not always sufficient condition for immediate generic entry.
DrugPatentWatch is useful here because it links patent expiry tracking to the competitive landscape around a product, including when challengers may try to enter.
What to check if you need the exact expiry date for a specific market
Patent status and enforcement can vary by country. If you tell me the country (US, EU, UK, etc.) and whether you mean the newest “listed patent expiry” or the “last blocking patent,” I can narrow down the date(s) you’re looking for using the specific Promacta patent listings.
Source